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Massive adipose tissue depositions in the abdomen and 
thorax sufﬁ  cient to interfere with respiration developed in a 
patient with multiple medical problems. Biopsy of adipose 
tissue identiﬁ  ed human adenovirus 36 (Adv 36) DNA. Adv 36 
causes adipogenesis in animals and humans. Development 
of massive lipomatosis may be caused by Adv 36.
I
nfection with human adenovirus 36 (Adv 36) has been 
reported to cause a large accumulation of fat in 4 animals 
(chickens, mice, rats, and monkeys) (1–3). Selective depo-
sition of visceral fat disproportional to total fat deposition 
was observed in some studies. The increase in visceral fat 
or total body fat in infected animals compared with unin-
fected animals was >100% in some experiments (1–3). Of 
animals that were infected, 60%–100% became obese com-
pared with uninfected animals (1–4). Obesity was deﬁ  ned 
as a weight or fat content greater than the 85th percentile of 
the uninfected animals.
Several human studies have shown a correlation of an-
tibodies to Adv 36 and obesity (4–8). In 1 study of >500 
persons, 30% of obese persons and 11% of lean persons 
had antibodies to Adv 36 (4). The body weight of infected 
persons was ≈25 kg heavier than that of uninfected persons 
(4). In 26 pairs of twins with discordant Adv 36 antibody 
status, infected twins were heavier and fatter (4). In a group 
of obese school children from South Korea, 30% had an-
tibodies to Adv 36, and infected children had higher body 
mass index z-scores than uninfected children (5). However, 
in animals and adults in the United States, serum choles-
terol and triglyceride levels were paradoxically reduced, 
despite the obesity (1–4). Recent reports of adults in Italy 
and children in South Korea support the association of Adv 
36 and obesity, and show that Adv 36 is more common in 
obese persons; prevalence ranges from 29% to 65% (6,7).
The mechanisms responsible for the increased adipos-
ity are changes in gene expression of multiple enzymes and 
transcription factors by the virus (8–15). In adipocytes, the 
sterol regulatory element binding protein pathway is in-
creased, resulting in increases in levels of sterol regulatory 
element binding protein 1 and fatty acid synthase. Because 
levels of transcription factor CCAAT/enhancer binding 
protein-β, peroxisome proliferator-activated receptor-γ, 
and lipoprotein lipase are also increased, lipid transport 
into cells and fatty acid synthesis within cells is increased 
(8–15). In muscle cells, gene expression of glucose trans-
porters Glut 1 and Glut 4 and phosphoinositide 3-kinase is 
increased, which results in noninsulin-mediated increases 
in glucose transport (14).
These changes are thought to be caused by the action 
of the Adv 36 open reading frame 1 early region 4 gene and 
may be blocked by small interfering RNA or the antiviral 
drug cidofovir (11,13). When the open reading frame 1 ear-
ly region 4 gene was transferred to a retrovirus and inserted 
into preadipocytes in vitro, the gene was capable of induc-
ing the enzymes and enhancing fat accumulation (13).
Adv 36 DNA persists in multiple tissues of infected 
animals for long periods after initial infection (3). Viral 
DNA was isolated from brain, lung, liver, muscle, and 
adipose tissue of monkeys 7 months after initial infection, 
long after the active virus has disappeared from blood and 
feces (3). The virus DNA apparently continues to alter gene 
expression chronically in tissues.
We report a patient with massive fat deposits in the 
thorax and abdomen. We postulate that these abnormal adi-
pose tissue deposits were caused by Adv 36 infection.
The Patient
The patient, a 62-year old man who was diagnosed 
with high-grade large cell lymphoma in 1999, received 
multidrug (cyclophosphamide, doxorubicin, vincristine, 
and prednisolone) chemotherapy, central nervous system 
prophylaxis with cytarabine, and high-dose methotrexate. 
In February 2000, he underwent autologous bone marrow 
transplantation and received a conditioning regimen of 
etoposide, cytoxan, and fractionated total-body irradiation. 
Hypothyroidism, chemoradiation-induced hypogonadism, 
and adrenal insufﬁ  ciency developed in the patient, which 
required chronic glucocorticoid replacement.
During the next 7 years, prostate cancer, rectal ulcer 
necessitating colon diversion, hemolytic anemia, thrombo-
cytopenia, myelodysplastic syndrome, and diabetes melli-
tus developed in the patient; he was treated with insulin 
for the diabetes. He was hospitalized for respiratory insuf-
ﬁ  ciency in August, 2007, which was thought to be caused 
or exacerbated by massive intrathoracic and intraabdomi-
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nal fat deposits. He had obesity of his neck, lateral chest, 
and abdomen, but limited subcutaneous fat in his abdomen 
and upper extremities. He had no buffalo hump, round fa-
cies, or other signs of Cushing syndrome. The patient had 
tachycardia with mufﬂ  ed heart sounds, dullness in the base 
of the right chest, and bibasilar diminished breath sounds. 
A computed tomography scan of the chest and abdomen 
showed fatty densities extending into the intrabdominal, 
intraperitoneal, and retroperitoneal areas and herniating 
through the esophageal hiatus into the mediastinum (Figure 
1). These fatty densities extended within the pericardium 
without deﬁ  nite pericardial effusion.
The patient’s weight was 113 kg, height 183 cm, body 
mass index 34, waist circumference 145 cm, and hip cir-
cumference 111 cm. Laboratory tests showed triglycerides 
1.356 mmol/L, total cholesterol 2.2015 mmol/L, high-den-
sity lipoprotein cholesterol 0.5957 mmol/L, and low-densi-
ty lipoprotein cholesterol 0.9842 mmol/L. The serum lipids 
values represent marked decreases from previous measure-
ments. In December 2002, his low-density lipoprotein cho-
lesterol level was 2.7412 mmol/L. In April 2007, his serum 
triglyceride level was 4.92244 mmol/L. The result of a test 
for serum immunoglobulin (Ig) M against adenoviruses 
was negative (0.07 IU), and the result of a test for serum 
IgG was positive (2.18 IU). 
Infection with Adv 36 causing disseminated lipoma-
tosis was suspected. A subcutaneous fat biopsy specimen 
was assayed for Adv 36 DNA by nested PCR (4). Three of 
4 adipose tissue samples showed a band compatible with 
Adv 36 DNA. Water controls in the assay had negative 
results. A HaeIII digest of the presumed Adv 36 DNA band 
showed digestion at the expected site and yielded 2 bands 
of equal size (Figure 2). Sequencing of the DNA band by 
the Virginia Commonwealth University Massey Cancer 
Center Molecular Biology Core (Richmond, VA, USA) 
identiﬁ  ed the sequence as Adv 36 DNA.
As a control, samples of adipose tissue obtained by 
needle fat biopsy from 12 obese persons without abnormal 
adipose tissue deposits were evaluated by nested PCR and 
quantitative PCR by using proprietary Taqman primers and 
probe (Obetech, Richmond, VA, USA). These persons pro-
vided written informed consent. Samples for quantitative 
PCR were analyzed with an ABI Step One PCR apparatus 
(Applied Biosystems, Foster City, CA, USA). Two of the 8 
samples assayed by nested PCR were positive and 5 of 12 
samples assayed by quantitative PCR were positive. The 
prevalence of Adv 36 infection identiﬁ  ed by PCR was simi-
lar to that identiﬁ  ed by serum neutralization in obese adults 
in the United States (5).
Conclusions
Adv 36 DNA in the adipose tissue of this patient docu-
ments that he was infected with this virus. The propensity 
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Figure 2. HaeIII digestion of adenovirus 36 (Adv 36) DNA PCR 
products of the patient. Lane 1, molecular size marker; lane 2, 
HaeIII digest of Adv 36 DNA; lane 3, undigested Adv 36 DNA.
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Figure 1. Computed tomography scans of the patient, showing 
marked visceral adipose tissue in the abdomen (A) and thorax (B). 
Diffuse intrabadominal, retroperitoneal lipomatosis, and herniation 
of the mediastinum can be seen through the esophageal hiatus. 
Intrapericardial adipose inﬁ   ltration and adipose tissue bilaterally 
are seen within the pleura.of Adv 36 to increase visceral adipose tissue in experimen-
tally infected animals suggests that the abnormal adipose 
tissue deposits within the abdomen and chest cavities and 
in the subcutaneous spaces of the chest and neck could be 
caused by Adv 36 infection. He was being treated with re-
placement corticosteroids but did not have signs of Cush-
ing syndrome.
More research is needed to determine if Adv 36 plays 
a role in abnormal adipose tissue deposits/lipomatosis. If 
Adv 36 is found to be a cause, research is needed to identify 
effective antiviral agents with a more tolerable side effect 
proﬁ  le. Cidofovir is effective against Adv 36 in vitro, but 
has major side effects in humans.
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